Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARTA T BOGNAR

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1336102425
CMS profile
106133
Location
GAINESVILLE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$3,401.56

191 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,401.56 191

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARTA T BOGNAR

NPI 1336102425 · CMS profile ID 106133

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

GAINESVILLE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336102425?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARTA T BOGNAR, NPI 1336102425, CMS profile ID 106133. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336102425?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MARTA T BOGNAR, NPI 1336102425, CMS profile ID 106133. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336102425?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MARTA T BOGNAR, NPI 1336102425, CMS profile ID 106133, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1336102425?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

191 matching records · $3,401.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 191 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 191.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $8.1206/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537029 CMS
Novartis Pharmaceuticals Corporation $18.0006/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537027 CMS
Aurinia Pharma U.S., Inc. $103.6606/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954067207 CMS
ABBVIE INC. $23.5906/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630351 CMS
Lilly USA, LLC $15.6306/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918189437 CMS
Janssen Biotech, Inc. $17.0906/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885816433 CMS
Amgen Inc. $19.6506/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939457193 CMS
Novartis Pharmaceuticals Corporation $9.4805/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537025 CMS
E.R. Squibb & Sons, L.L.C. $10.8805/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932754965 CMS
ABBVIE INC. $13.2005/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630349 CMS
Novartis Pharmaceuticals Corporation $18.7605/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537023 CMS
Novartis Pharmaceuticals Corporation $18.5605/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537021 CMS
Novartis Pharmaceuticals Corporation $24.6605/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537019 CMS
PFIZER INC. $16.4905/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949162441 CMS
Sobi, Inc $29.4205/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940357989 CMS
Amgen Inc. $11.4905/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939457191 CMS
Horizon Therapeutics plc $23.8405/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937595841 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.6405/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887483699 CMS
Novartis Pharmaceuticals Corporation $9.4805/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537017 CMS
Janssen Biotech, Inc. $14.8405/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885816475 CMS
Genentech USA, Inc. $26.7205/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950783867 CMS
Lilly USA, LLC $17.0004/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918239149 CMS
Aurinia Pharma U.S., Inc. $17.9504/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954067203 CMS
Novartis Pharmaceuticals Corporation $12.7004/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537015 CMS
Radius Health, Inc. $20.9304/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954967221 CMS
Novartis Pharmaceuticals Corporation $4.1204/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537013 CMS
UCB, Inc. $14.4804/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907989129 CMS
ABBVIE INC. $24.7904/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630347 CMS
Octapharma USA, Inc. $16.4104/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937549899 CMS
ABBVIE INC. $20.2404/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630343 CMS
ABBVIE INC. $0.4604/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630345 CMS
Janssen Biotech, Inc. $27.1104/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885816439 CMS
ABBVIE INC. $19.7604/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630341 CMS
E.R. Squibb & Sons, L.L.C. $16.2004/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932754959 CMS
ABBVIE INC. $14.8504/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630339 CMS
GlaxoSmithKline, LLC. $22.7704/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945080495 CMS
UCB, Inc. $16.3803/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907989131 CMS
ABBVIE INC. $15.9903/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630337 CMS
Aurinia Pharma U.S., Inc. $15.4903/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954067201 CMS
ABBVIE INC. $28.0203/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630335 CMS
Novartis Pharmaceuticals Corporation $18.8803/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537011 CMS
Novartis Pharmaceuticals Corporation $8.1603/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537009 CMS
ABBVIE INC. $20.0003/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630333 CMS
Novartis Pharmaceuticals Corporation $20.4603/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537007 CMS
Amgen Inc. $9.1603/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939457199 CMS
Novartis Pharmaceuticals Corporation $7.6403/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893537005 CMS
Amgen Inc. $20.0103/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939457197 CMS
PFIZER INC. $20.4603/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949160911 CMS
ABBVIE INC. $17.5703/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630331 CMS
ABBVIE INC. $15.2303/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890630329 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,494.67 157
PY2020 $661.43 37
PY2021 $2,590.39 169
PY2022 $3,401.56 191
PY2023 $3,680.19 201
PY2024 $3,818.35 192
PY2025 $3,402.16 158

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $374.70 1
PY2025 Principal investigator $197,409.25 25
PY2024 Recipient $9,963.80 1
PY2024 Principal investigator $204,319.46 76
PY2023 Principal investigator $115,976.16 60
PY2022 Principal investigator $93,897.32 61
PY2021 Principal investigator $14,465.67 34
PY2020 Principal investigator $11,089.50 11
PY2019 Recipient $1,261.99 9
PY2019 Principal investigator $61,642.23 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,333.56 12/17/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434574
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,524.56 11/19/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434582
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $13,843.38 10/02/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434590
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $983.30 08/14/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434603
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $449.23 07/25/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434631
Principal investigator 1 Eli Lilly and Company $5,489.00 07/23/2025 Non-covered Recipient Entity
SOUTHEASTERN RHEUMATOLOGY ALLIANCE DBA ARTHRITIS CENTER OF NORTH GEORGIA
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187890902
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,714.81 07/23/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434571
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,177.25 07/11/2025 Non-covered Recipient Entity
ARTICULARIS HEALTHCARE GROUP INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430848
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $303.58 07/02/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434628
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $13,913.36 06/25/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434579
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $770.40 04/24/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434624
Recipient Eli Lilly and Company $374.70 04/23/2025 Covered Recipient Physician EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187873497
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,347.85 04/23/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434598
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,347.85 04/02/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434594
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,707.00 03/17/2025 Non-covered Recipient Entity
ARTICULARIS HEALTHCARE GROUP INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430850
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,187.37 03/14/2025 Non-covered Recipient Entity
ARTICULARIS HEALTHCARE GROUP INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430842
Principal investigator 1 Eli Lilly and Company $537.00 03/10/2025 Non-covered Recipient Entity
LOW COUNTRY RHEUMATOLOGY PA
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187884966
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,950.12 03/10/2025 Non-covered Recipient Entity
ARTICULARIS HEALTHCARE GROUP INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430844
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,893.75 03/03/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434586
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $326.84 02/28/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434620
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $87.21 02/27/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434615
Principal investigator 1 Eli Lilly and Company $1,454.76 02/25/2025 Non-covered Recipient Entity
LOW COUNTRY RHEUMATOLOGY PA
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187884186
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $341.06 02/11/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434612
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $11,017.12 02/05/2025 Non-covered Recipient Entity
ARTICULARIS HEALTHCARE GROUP INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430846
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,949.89 01/27/2025 Non-covered Recipient Entity
Southeastern Rheumatology Alliacne
INSPIRE LTE study No dispute reported 06/30/2026 1246434608
Principal investigator 1 Eli Lilly and Company $100,759.00 01/07/2025 Non-covered Recipient Entity
SOUTHEASTERN RHEUMATOLOGY ALLIANCE DBA ARTHRITIS CENTER OF NORTH GEORGIA
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187891354